spread
new
variant
influenza
viru
northern
hemispher
earlier
time
usual
season
influenza
previou
year
highlight
limit
knowledg
concern
aetiolog
acut
respiratori
ill
outsid
influenza
outbreak
earli
septemb
report
ill
increas
medic
surveil
franc
european
countri
detect
pandem
influenza
viru
remain
sporad
lind
et
al
find
attribut
circul
respiratori
virus
lesser
extent
may
associ
increas
propens
patient
ill
seek
medic
advic
due
increas
anxieti
pandem
context
find
also
observ
ill
incid
rate
report
french
sentinel
network
turbelin
et
al
sentinel
network
continu
epidemiolog
surveil
system
base
gener
practition
gp
oper
sinc
franc
consist
sampl
gp
throughout
franc
particip
week
continu
surveil
valleron
et
al
gp
particip
sentinel
network
repres
whole
french
gp
popul
regard
age
locat
type
ruralurban
kind
practic
alonepluridisciplinari
chauvin
valleron
main
object
french
sentinel
network
provid
nation
health
author
near
inform
sever
event
occur
commun
includ
ill
full
list
event
see
http
wwwsentiwebfr
event
report
sentinel
gp
dedic
websit
aggreg
differ
spatial
tempor
level
use
inform
health
author
sentinel
network
ill
case
defin
basi
clinic
sign
virolog
collect
carri
routin
given
need
improv
virolog
surveil
first
pandem
wave
span
septemb
decemb
franc
feasibl
integr
diagnosi
respiratori
virus
clinic
surveil
ill
french
sentinel
network
test
secondari
object
virolog
clinic
data
analys
three
virolog
laboratori
particip
studi
subset
volunt
gp
locat
mainland
franc
recruit
basi
particip
continu
surveil
sentinel
network
gp
distribut
depart
administr
unit
franc
gp
particip
present
studi
differ
gp
sentinel
network
respect
age
year
vs
year
p
gender
male
vs
p
urbanrur
distribut
urban
vs
rural
vs
p
year
inscript
sentinel
network
year
vs
year
p
pilot
studi
carri
week
januari
februari
end
french
epidem
enrol
volunt
gp
receiv
swab
studi
materi
includ
everi
first
patient
week
medic
visit
ill
sentinel
network
sudden
fever
respiratori
symptom
myalgia
addit
criteria
time
symptom
onset
visit
less
hr
sampl
collect
perform
swab
elitech
franc
nasopharyng
swab
sent
mail
ml
viral
transport
medium
within
day
one
three
virolog
laboratori
particip
studi
detail
demograph
clinic
data
time
onset
symptom
report
symptom
physic
find
influenza
vaccin
statu
obtain
patient
medic
visit
follow
rna
dna
extract
clinic
specimen
use
either
autom
magna
pure
lc
total
nucleic
acid
high
perform
kit
roch
diagnost
meylan
franc
biorobot
viru
mini
kit
qiagen
courtaboeuf
franc
sampl
test
simultan
detect
panel
respiratori
viral
pathogen
use
microarray
detect
assay
pneumovir
fluavir
version
genomica
madrid
spain
pneumovir
allow
detect
respiratori
virus
distinguish
season
influenza
subtyp
fluavir
kit
abl
type
distinguish
influenza
viru
subtyp
season
influenza
viru
respiratori
sampl
test
simultan
use
two
kit
combin
two
system
allow
simultan
detect
adenoviru
av
bocaviru
hbov
coronaviru
hcov
enteroviru
echoviru
ev
influenza
influenza
b
influenza
c
metapneumoviru
hmpva
hmpvb
parainfluenza
piv
respiratori
syncyti
viru
rsva
rsvb
rhinoviru
rv
techniqu
includ
intern
control
test
effici
amplif
process
detect
presenc
inhibit
product
sensit
specif
multiplex
assay
simultan
detect
panel
respiratori
viral
pathogen
previous
report
renoi
et
al
surveil
virolog
result
number
sampl
posit
sampl
type
subtyp
virus
isol
weekli
avail
websit
week
follow
sampl
collect
week
gp
also
receiv
virolog
result
herhi
patient
secur
studi
websit
interv
specimen
collect
avail
result
gp
day
final
survey
gp
includ
patient
describ
reason
lack
sampl
collect
perform
anoth
survey
perform
evalu
gp
satisfact
pilot
studi
includ
patient
patient
least
one
viru
detect
posit
patient
compar
patient
viru
detect
neg
patient
factor
sign
associ
posit
virus
frequent
isol
studi
fisher
exact
test
use
compar
independ
categor
variabl
test
use
compar
continu
variabl
logist
regress
model
use
binomi
outcom
odd
ratio
confid
interv
estim
gp
collect
nasopharyng
sampl
base
clinic
data
report
gp
sampl
collect
patient
ill
defin
surveil
network
maximum
number
sampl
collect
week
januari
januari
n
gp
provid
one
sampl
eleven
provid
two
sampl
ten
gp
provid
three
sampl
three
gp
provid
four
sampl
gp
collect
sampl
n
differ
n
respect
age
year
vs
year
p
gender
male
vs
p
year
inscript
sentinel
network
year
vs
year
p
percent
gp
respond
satisfact
survey
gp
satisfi
swab
collect
instruct
found
dedic
studi
websit
use
follow
develop
studi
consult
instruct
gp
satisfi
feedback
result
gp
collect
nasopharyng
sampl
four
item
propos
explain
reason
particip
lack
ill
case
studi
period
lack
time
studi
complex
declin
particip
percent
gp
declar
collect
sampl
lack
ill
case
studi
period
report
interest
particip
studi
four
gp
particip
lack
time
declin
particip
follow
phase
studi
median
age
patient
ill
patient
year
male
patient
differ
case
ill
report
sentinel
network
studi
period
n
regard
age
p
influenza
vaccin
statu
p
howev
proport
men
higher
sampl
case
ill
report
network
men
p
note
includ
patient
children
age
compar
proport
children
gener
french
popul
indic
children
time
like
adult
includ
sampl
patient
ill
seven
sampl
exclud
sinc
virolog
result
interpret
fluavir
n
microarray
pneumovir
microarray
n
undetect
intern
control
among
remain
ill
case
virus
detect
nasopharyng
sampl
patient
rsv
hmpv
hcov
influenza
rv
hbov
av
influenza
b
influenza
piv
tabl
one
viru
detect
four
patient
tabl
age
distribut
year
differ
significantli
posit
neg
patient
posit
patient
younger
neg
patient
ic
p
patient
age
year
n
posit
one
respiratori
virus
among
eight
posit
diagnosi
rsvb
infect
fig
common
clinic
find
patient
infect
hmpv
n
rsv
n
cough
n
n
rhinorrea
n
n
fatigu
n
n
myalgia
n
n
patient
tabl
median
age
year
differ
clinic
patient
despit
small
number
sampl
includ
present
pilot
studi
show
feasibl
combin
microarray
detect
respiratori
viru
infect
clinic
surveil
ill
order
provid
complet
understand
epidemiolog
virus
commun
combin
commun
virolog
clinic
surveil
influenza
rsv
implement
sever
countri
notabl
franc
group
dobserv
de
la
gripp
grog
surveil
system
oper
year
gp
pediatrician
perform
virolog
diagnosi
influenza
patient
acut
respiratori
ill
dab
similar
network
launch
european
countri
eg
uk
switzerland
itali
spain
http
wwwecdceuropeeu
knowledg
surveil
system
combin
simultan
diagnosi
larg
number
respiratori
virus
clinic
surveil
ill
use
case
definit
simultan
diagnosi
larg
number
respiratori
virus
associ
clinic
surveil
allow
extrapol
preval
rate
viru
patient
match
clinic
case
definit
nationwid
level
facilit
interpret
surveil
data
addit
technic
viewpoint
microarray
assay
requir
fewer
human
intervent
hr
time
save
compar
allow
test
sampl
per
run
min
setup
exclud
rna
extract
result
avail
next
day
frobert
et
al
raymond
et
al
thu
surveil
system
could
sustain
period
number
case
ill
much
higher
although
obtain
result
day
would
ideal
scenario
eas
implement
higher
throughput
import
factor
especi
laboratori
raymond
et
al
present
pilot
studi
optim
shorten
delay
collect
deliv
result
gp
reason
actual
delay
day
howev
result
surveil
made
avail
week
follow
sampl
collect
notabl
result
aggreg
preced
week
feasibl
programm
question
given
fact
gp
collect
least
one
sampl
although
demonstr
yet
evalu
winter
small
number
particip
first
season
might
easili
explain
case
definit
collect
specimen
rather
stringent
includ
elev
fever
note
gp
agre
continu
particip
programm
winter
among
sampl
test
result
seven
sampl
avail
uncertain
result
mani
case
failur
identif
could
result
failur
nucleic
acid
amplif
step
rather
failur
microarray
townsend
et
al
even
technic
train
necessari
avoid
fals
posit
result
insuffici
wash
overexposur
array
frobert
et
al
exclud
sampl
posit
least
one
viru
proport
posit
diagnosi
compar
find
studi
use
combin
classic
cell
cultur
techniqu
sampl
posit
follin
et
al
heikkinen
et
al
et
al
et
al
noteworthi
clinic
criteria
use
sampl
collect
studi
includ
broad
spectrum
respiratori
symptom
criteria
ill
rather
narrowspecif
therefor
number
posit
specimen
alter
select
patient
strict
case
definit
hand
result
may
occur
adult
popul
could
consequ
insuffici
qualiti
sampl
collect
lack
sensit
laboratori
techniqu
nevertheless
recent
studi
valid
perform
commerci
kit
use
present
studi
renoi
et
al
neg
result
also
due
unknown
known
respiratori
pathogen
eg
parechoviru
polyomaviru
ki
wu
human
coronaviru
pneumonia
c
pneumonia
proport
undiagnos
case
line
found
survey
hasman
et
al
et
al
appeal
complementari
virolog
investig
use
exampl
high
throughput
method
eg
pyrosequenc
method
deyd
et
al
mass
spectrometri
chen
et
al
high
resolut
melt
hrm
techniqu
varilla
et
al
padlock
probe
wu
tang
investig
found
age
associ
chanc
posit
rate
posit
younger
patient
year
rsv
hmpv
frequent
detect
virus
similar
find
obtain
set
attribut
develop
immun
statu
young
children
vulner
infect
raboni
et
al
given
temperatur
criteria
use
ill
children
overrepres
comparison
adult
rel
gener
popul
figur
well
line
current
knowledg
fever
usual
higher
children
adult
feigin
et
al
howev
age
distribut
patient
differ
age
distribut
report
ill
case
network
period
therefor
select
bia
relat
age
exclud
moreov
sentinel
network
involv
gp
involv
pediatrician
explain
low
proport
young
children
year
sampl
substanti
proport
adult
subject
rsv
hmpv
found
studi
find
also
consist
report
rsv
detect
adult
patient
medic
visit
falsey
et
al
zambon
et
al
hmpv
adult
particip
prospect
walsh
et
al
present
studi
signific
differ
clinic
characterist
patient
infect
hmpv
rsv
viral
infect
number
patient
group
low
comparison
may
underpow
previou
studi
heikkinen
et
al
fact
common
confirm
studi
hmpv
occur
twice
rsva
influenza
b
respect
associ
sever
sign
report
elsewher
frobert
et
al
wolf
et
al
number
event
low
reach
conclus
addit
dna
microarray
detect
techniqu
qualit
quantit
possibl
determin
viru
predomin
concomit
respiratori
viral
infect
conclus
although
feasibl
formal
demonstr
eg
respect
set
criteria
studi
show
virolog
diagnosi
respiratori
virus
combin
surveil
clinic
ill
gener
practic
approach
use
routin
could
help
describ
better
season
commun
burden
respiratori
virus
assess
clinic
outcom
singl
multipl
viral
infect
